Drugs / human rabies vaccine (Vero Cells)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07672626 Comparator | Jul 2022 → Aug 2024 | — | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | human rabies vaccine (Vero Cells) | “The tested vaccine is a lyophilized human rabies vaccine (Vero Cells) produced by Shanghai Rongsheng Biotech Co., Ltd.” NCT07672626 ↗ |
| Modality | Vaccine | “human rabies vaccine” NCT07672626 ↗ |
| Route | Intramuscular | “one intramuscular dose administered on days 0, 3, 7, 14, and 28 respectively” NCT07672626 ↗ |